nai_header

nai_headerbuttons

HomeAbout NAIManufacturingNewsInvestor RelationsContact UsFAQFAQ
   About Us
   Executive Team
   Board of Directors
   Bus. Development
   
   Manufacturing
   Global Operations
   North America
   Europe & Asia
   Investors
   Financial Data
   Annual Report
   Corp. Governance
   
 
   Certifications
   TGA Certification
   GMP Standards
   Publications
   News & Blog
   News
   CEO's Blog
   Industry Links
   

Natural Alternatives International, Inc. Announces Issuance of New U.S. Patent Covering CarnoSyn(R) Beta-alanine

SAN MARCOS, Calif., March 21, 2012 -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,129,422 entitled "Methods and compositions for increasing the anaerobic working capacity in tissues." The new patent becomes part of the portfolio covering NAI's CarnoSyn® beta-alanine product.

Mark A. LeDoux, NAI's CEO and Chairman of the Board, said, "The new patent enhances NAI's portfolio by continuing to offer a superior and proven dietary supplement for human athleticism and health." He went on to say, "The new patent also offers NAI the ability to move into animal dietary supplementation. This new patent continues the recognition that patented beta-alanine based dietary supplements are uniquely beneficial to humans and animals alike."

NAI's new patent contains claims directed, in part, to methods of avoiding or delaying the onset of muscular fatigue through the use of beta-alanine compositions in several formulations. The newly patented methods cover humans as well as certain animals. The methods require the use of beta-alanine that is not part of a dipeptide, polypeptide or oligopeptide and is in the form of a dietary supplement. Esters or amides of beta-alanine, which are not part of a dipeptide, polypeptide or oligopeptide, may also be employed. Additional active agents, such as carbohydrates, L-histidine, insulin and creatine, may also be present. A list of NAI's intellectual property rights may be found at http://www.carnosyn.com.

The only licensed distributor of NAI's CarnoSyn® beta-alanine product is Compound Solutions, Inc., a science and marketing based distributor of raw materials to the sports nutrition, dietary supplement, food, pharmaceutical and personal care industries.

NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://www.nai-online.com.

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.